| Date | Partners | Compound / Disease area / Development phase | Type of agreement | Nature / Financial terms |
|---|---|---|---|---|
| 2010-06-15 | Basilea Pharmaceutical (Switzerland) Almirall (Spain) |
Toctino® (alitretinoin) / severe chronic hand eczema |
commercialization/ distribution |
See details |
| 2010-06-14 | ExonHit Therapeutics (France) Genmab (Denmark) |
splice variant developed using SpliceArray® technology / breast cancer | R&D licensing |
See details |
| 2010-06-10 | Protagen (Germany) Bayer Schering Pharma (Germany) |
novel biomarkers / endometriosis | R&D other |
See details |
| 2010-06-08 | Vivalis (France) Sanofi Pasteur (France) |
human monoclonal antibodies / undisclosed infectious diseases | R&D licensing development other |
See details |
| 2010-06-08 | Cellectis bioresearch (France) Lonza (Switzerland) |
commercialization/ distribution development |
See details | |
| 2010-06-08 | Zealand Pharma (Denmark) Sanofi Aventis (France) |
lixisenatide (GLP-1 (glucagon-like-peptide-1) receptor agonist) / type 2 diabetes |
R&D commercialization/ distribution development |
See details |
| 2010-06-07 | Lonza (Switzerland) California Stem Cell (USA) |
licensing other |
See details | |
| 2010-06-04 | Ascenta Therapeutics (USA) Sanofi-Aventis (France) |
orally-active, small-molecule drug candidates inhibiting the interaction between HDM2 (Human Double Minute 2) and p53. / cancer | R&D licensing manufacturing commercialization/ distribution development |
See details |
| 2010-06-01 | Orexo (Sweden) Ortho-McNeil-Janssen Pharmaceuticals (USA) Janssen Pharmaceutica (Belgium) |
OX-CLI and OX-ESI programs from Orexo and a third internal program from Ortho-McNeil-Janssen Pharmaceuticals. This latest program is focusing on discovering and developing innovative small-molecules against an undisclosed target. / asthma, chronic obstructive pulmonary disease, and other inflammatory diseases. | R&D licensing commercialization/ distribution development marketing/ promotion |
See details |
| 2010-05-26 | CEVEC Pharmaceuticals (Germany) Pevion Biotech (Switzerland) |
CAP-T™ cell expression technology The technology is based on CAP® cells, a human immortalized cell line for stable protein production derived from amniocytes and developed by CEVEC. These non-tumor origin cell lines exhibit high protein expression levels even for difficult to express proteins. They have been adapted to serum-free suspension culture and show post-translational modifications that are human-like, including authentic human glycosylation patterns. / infectious diseases |
licensing other |
See details |
| 2010-05-26 | Massachusetts Institute of Technology Center for Biomedical Innovation (USA) Sanofi-Aventis (France) |
R&D |
See details | |
| 2010-05-25 | Aureus Pharma (France) Ariadne (USA) |
R&D commercialization/ distribution other |
See details | |
| 2010-05-18 | TcLand Expression (France) Hospices Civils de Lyon (France) |
novel biomarkers / rheumatoid arthritis | R&D |
See details |
| 2010-05-17 | ElexoPharm (Germany) Merck & Co (USA) |
novel candidates targeting aldosterone synthase / cardiovascular disease | R&D licensing commercialization/ distribution development |
See details |
| 2010-05-12 | Biotage (Sweden) University of Copenhagen (Denmark) |
peptide synthesis and protein chemistry | R&D |
See details |
